Press Releases

Mithra Launches its Product Tibelia on the Global Market
22 December 2016
EN FR

Success for Myring European Clinical Trial
8 December 2016
EN FR

Mithra Signs a LOI for the Chinese Rights on Estetrol in Women’s Health with the Market Leader in Women’s Health in China, Zhejiang Xianju Pharmaceutical
16 November 2016
EN FR

Mithra Announces the Leave of its CFO
31 October 2016
EN FR

Mithra huldigt zijn nieuw ontwikkelings- en productiecentrum in Flémalle in
30 September 2016
FR NL

Mithra Will Propose Christiane Malcorps as new Independent Board Member / Phase III Clinical Study for Estelle® in us Launched With First Randomized Patient
23 September 2016
EN FR

The Contraception Journal Publishes a Scientific Paper on the Haemostatic Effects of Estetrol; Results Are Encouraging for the Estelle® Product Candidate
8 September 2016
EN FR

Mithra Pharmaceuticals Announces its First Half 2016 Financial Results and Operational Progress
1 September 2016
EN FR

Half Year 2016 Results
1 September 2016
EN FR

Mithra Signs its First Major Partnership with the Japanese Leader in Women Health Fuji Pharma to Commercialize Estelle® in Japan and ASEAN
31 August 2016
EN FR

Marc Coucke Appointed Chairman of Mithra’s Board of Directors
26 August 2016
EN FR

Mithra Continues to Confirm its Contraception Market Leader Position in Belgium
26 July 2016
EN FR

Green Light from FDA for the Launch of Estelle®(E4/DRSP) Phase III Study in the United States
22 July 2016
EN FR

Canada Approves Clinical Trial Application for Estelle® (E4/DRSP) Phase III Study
20 July 2016
EN FR

Mithra Obtains a Marketing Authorisation for its Own Product Tibelia® in Spain for Which it has Two Commercial Agreements
5 July 2016
EN FR

First Patient Screened for the European Product Candidate Estelle® (E4/DRSP) Phase III Clinical Study: the Phase III Has Started in Europe Ahead of Schedule
30 June 2016
EN FR

Mithra Pharmaceuticals Hosts its 2016 Investor Day and Reaffirms its Strategy for the Upcoming Years
29 June 2016
EN FR

Mithra Signs a License and Supply Agreement with Gedeon Richter for its product Tibelia® in 6 European Territories
28 June 2016
EN FR

Mithra Signs an LOI for the Japanese and ASEAN Rights on Estetrol in Women’s Health with the Market Leader in Japan, Fuji Pharmaceuticals
24 June 2016
EN FR

Mithra Pharmaceuticals to Host Investor Day Event on June 29th, 2016 in Brussels
25 May 2016
EN FR NL

Inauguration of the Mithra CDMO on September 30, 2016, Three Months Ahead of Schedule ; a Milestone That Bodes Well for GMP Approvals
18 May 2016
EN FR

Mithra Enrols its First 5 Patients for the Donesta® Phase II Clinical Study MIT-DO0001-C201
13 May 2016
EN FR

Mithra Launches Manufacturing of Myring First Technical and Clinical Batches
10 May 2016
EN FR

Mithra Recognized by the Scientific Community: the Contraception Journal Publishes a Scientific Article About E4 (Estetrol) FIESTA Phase II Study
4 May 2016
EN FR

Mithra’s European Advisory Board for Estelle Will Meet During the ESC Congress (European Society of Contraception) in Basel on May 4th 2016
3 May 2016
EN FR

3 Out of 5 European Countries Selected Have Fully Approved Protocol of Phase II Clinical Study Donesta®-Mit-Do001-C201. 8 Out of 9 European Countries Selected Have Fully Approved Protocol of Phase III Clinical Studies Estelle®- Mit-Es001-C301
29 April 2016
EN FR

Mithra Files Patent Applications for its Sublingual Form Based on Estetrol Thereby Extending its IP Position to Sublingual Formulations in Contraception and Menopause Until 2036
28 April 2016
EN FR

Mithra Pharmaceuticals Releases 2015 Annual Report and Invitation to its Ordinary General Shareholder’s Meeting
19 April 2016
EN FR

Annual Report 2015
19 April 2016
EN FR

Mithra Obtains Three Marketing Authorisations for its Product Tibelia®, one of Which in the United Kingdom Where it Signed a First License and Supply Agreement
13 April 2016
EN FR

FDA Feedback on SPA Estelle®: a New Step Closer to the Launch of Estelle® Phase III Pivotal Clinical Studies
5 April 2016
EN FR

Topline Results of Food Effect Study of the Product Candidate Estelle®, the New Combined Oral Contraceptive Composed of 15 mg of Estetrol (E4) and 3 mg of Drospirenone (DRSP)
1 April 2016
EN FR

Update on Zoreline® Projects Including Last Interim Results for the Pharmacodynamics Study of the 3-­‐Month Implant
31 March 2016
EN FR

Formulation Development of the Product Candidate Myring is Complete, Production of Clinical Batches for the Final Bioequivalence Study can Start
30 March 2016
EN FR

Already 4 European Countries Fully Approved Protocol of MIT-ES001-C301 Estelle Phase III Clinical Study
24 March 2016
EN FR

Mithra’s Tibelia® gets green light for market authorization in 14 European Countries, reinforces its CDMO ​production pipeline and demonstrates its development capabilities
10 March 2016
EN FR

Mithra Unveils its Business Plan to More Than 35 French Journalists in Presence of Roselyne Bachelot, Former France’s Health Minister
9 March 2016
EN FR

Lancering van de website Gyn&co
7 March 2016
FR NL

Press Release: Financial Results 2015
3 March 2016
EN FR

Financial Results 2015
3 March 2016
EN FR

Mithra Pharmaceuticals Announces the Appointment of an Estetrol Development Programs Director
16 February 2016
EN FR NL

Mithra Pharmaceuticals SA/NV Won PLG Business Development Award For 2015
8 February 2016
EN FR NL

Publication of a Transparency Notification Received by Mithra Pharmaceuticals SA/NV
22 January 2016
EN FR NL

Transparency Notification – Bart Versluys
22 January 2016
NL

Mithra is Meeting U.S. Institutional Investors at J.P. Morgan Conference
11 January 2016
EN FR

Mithra Pharmaceuticals licht een tipje van de sluier over de noden en verwachtingen van vrouwen rond vrouwelijke gezondheid
7 January 2016
FR NL